Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators
Autor: | Constantinos G. Hadjipanayis, Analiz Rodriguez, Jian Campian, Melanie Hayden Gephart, Daniel A. Orringer, Jennifer S. Yu, Ali Jalali, James Battiste, Gavin P. Dunn, Akash J. Patel, Peter E. Fecci, Dimitris G. Placantonakis, Eric C. Leuthardt, Albert H. Kim, Sunit Das, Kimberly B Hoang, Mario L. Suvà, Ralph G. Dacey, Milan G. Chheda, Greg Zipfel, Nduka Amankulor, Isaac Yang, Edjah K. Nduom |
---|---|
Rok vydání: | 2021 |
Předmět: |
Position statement
medicine.medical_specialty Stereotactic biopsy Biopsy 03 medical and health sciences 0302 clinical medicine medicine Humans Intensive care medicine Pseudoprogression medicine.diagnostic_test Brain Neoplasms business.industry Recurrent glioblastoma medicine.disease Clinical trial 030220 oncology & carcinogenesis Mutation Surgery Neurology (clinical) Personalized medicine Neoplasm Recurrence Local Glioblastoma business 030217 neurology & neurosurgery |
Zdroj: | Neurosurgery. 89:129-132 |
ISSN: | 1524-4040 0148-396X |
Popis: | Patients with glioblastoma (GBM) need bold new approaches to their treatment, yet progress has been hindered by a relative inability to dynamically track treatment response, mechanisms of resistance, evolution of targetable mutations, and changes in mutational burden. We are writing on behalf of a multidisciplinary group of academic neuro-oncology professionals who met at the collaborative Christopher Davidson Forum at Washington University in St Louis in the fall of 2019. We propose a dramatic but necessary change to the routine management of patients with GBM to advance the field: to routinely biopsy recurrent GBM at the time of presumed recurrence. Data derived from these samples will identify true recurrence vs treatment effect, avoid treatments with little chance of success, enable clinical trial access, and aid in the scientific advancement of our understanding of GBM. |
Databáze: | OpenAIRE |
Externí odkaz: |